Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IC 265

Next Previous
Drug Profile

IC 265

Alternative Names: IC-265

Latest Information Update: 04 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IACTA Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Eye disorder therapies
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 19 Dec 2023 Iacta Pharmaceuticals terminates phase II trial in Dry eyes in USA due to occurrence of adverse event (Ophthalmic) (NCT05992922)
  • 18 Oct 2023 Phase II trials in Dry eyes in USA (Ophthalmic) (NCT05992922)
  • 13 Oct 2022 IC 265 is still in phase II development for Allergic conjunctivitis and Dry eyes in USA (IACTA Pharmaceuticals pipeline, October 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top